Xiaosong Wang, M.D., Ph.D.

  • Associate Professor
  • Department of Pathology

Education & Training

  • B.S.,M.D. (equivalent), Biology and Medicine-China Medical University 2001
  • Ph.D. Bioinformatics,Molecular Biology, Immunology &Urology-Peking University Health Science Center 2006
  • Postdoc, Integrative Bioinformatics and Cancer Biology-University of Michigan 2010

Research Interest Summary

Apply a multiple disciplinary approach to detect driving genetic aberrations and viable therapeutic targets in cancer and develop the computational approaches for cancer precision medicine based on multi-omics datasets.

Research Categories

Research Interests

The mission of our laboratory is to apply a multiple disciplinary approach to detect driving genetic aberrations and viable therapeutic targets in cancer and develop the bioinformatics tools for cancer precision medicine on the basis of multi-omics datasets. Our multidisciplinary cancer research program combines integrative bioinformatics, cancer genetics, molecular cancer biology, and translational studies. We invented multiple integrative computational technologies to discover viable cancer targets from multi-omics datasets (see: http://www.cagenome.org), and we have built a strong integrated laboratory module to characterize and qualify these targets. Our wet-lab researches focus on translational cancer biology to identify new genetic targets in breast cancer and elucidate their biological function and clinical relevance.

Representative Publications

Kim JA, Tan Y, Wang X, Cao X, Veeraraghavan J, Liang Y, Edwards DP, Huang S, Pan X, Li K, Schiff R. and Wang XS#. Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers. Nature Communications. 2016 7:12991.

Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, Schiff R, Wang XS#, Li K#. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene 2016 10.1038/onc.2016.433.

Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, Maiti SN, Cooper LJN, Edwards DP, Contreras A, Hilsenbeck SG, Chang EC, Schiff R, Wang XS#. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers. Nature Communications. 2014 5:4577.

Xu QW, Zhao W, Wang Y, Sartor MA, Han DM, Deng JX, Ponnala R, Yang JY, Zhang QY, Liao GQ, Qu YM, Li L, Liu FF, Zhao HM, Yin YH, Chen WF, Zhang Y#, Wang XS#. An integrated genome-wide approach to discover tumor specific antigens as potential immunological and clinical targets in cancer. Cancer Research. 2012 72:6351-61.

Wang XS*, Shankar S*, Dhanasekaran SM*, Ateeq B, Prensner JR, Yocum AK, Pflueger D, Jing X, Fries DF, Han B, Li Yong, Cao Q, Cao X, Maher CA, Kumar SC, Demichelis F, Tewari AK, Kuefer R, Omenn GS, Palanisamy S, Rubin MA, Varambally S, Chinnaiyan AM. Characterization of KRAS Rearrangements in Metastatic Prostate Cancer. Cancer Discovery. 2011 1:35-43.

Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nature Biotechnology. 2009 27:1005-1011.

Wang XS*, Zhang Z*, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, Zhang Y, Xin DQ, Na YQ, Chen WF. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clinical Cancer Research. 2006 12:4851-8.

Wang XS*, Zhao H*, Xu Q, Jin W, Liu C, Zhang H, Huang Z, Zhang X, Zhang Y, Xin DQ, Simpson AJ, Old LJ, Na YQ, Zhao Y, Chen W. HPtaa database-potential target genes for clinical diagnosis and immunotherapy of human carcinoma. Nucleic Acids Research. 2006 34:D607-12.